Trial Profile
Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 29 Nov 2022 Planned End Date changed from 31 Dec 2021 to 31 Jan 2024.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 20 Oct 2021 Status changed from recruiting to active, no longer recruiting.